BHC Stock Analysis: Bausch Health Companies | NYSE
Drug Manufacturers - Specialty & Generic | NYSE, USA | Market Cap: 2.337m USD | 12M Return: -13.3% | CA0717341071 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 17.8M
EPS Trend: 84.9%
Qual. Beats: 1
Rev. Trend: 99.4%
Qual. Beats: 4
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Bausch Health Companies Inc. (BHC) is a Canadian-headquartered, diversified specialty pharmaceutical and medical device company that operates through five reporting segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Its product portfolio spans a broad set of therapeutic areas, including gastroenterology, hepatology, neurology, dermatology, generic and branded generic pharmaceuticals, dentistry, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The geographic footprint is wide, with sales across the United States, Canada, China, Mexico, several major European markets (France, Germany, the UK, Spain, Italy, Poland), and select Asia-Pacific and other international regions.
The company was originally known as Valeant Pharmaceuticals International, Inc. and rebranded as Bausch Health Companies Inc. in July 2018; it has been publicly listed since 1994. As a small-cap healthcare name (market capitalization of approximately $1.86 billion USD) classified within the GICS Pharmaceuticals sub-industry, BHCs business model combines prescription specialty drugs, generics, consumer health products, and medical devices-a structure typical of diversified pharma companies that balance higher-margin specialty therapeutics with volume-driven generics and OTC franchises. Its Bausch + Lomb segment also gives the company a meaningful position in the global eye health market, one of the larger and more defensible niches within healthcare, while its aesthetic medical device operations place it within the growing medical aesthetics sector.
- Bausch + Lomb stake value drives equity narrative
- Salix Xifaxan cash flow funds aggressive debt paydown
- High leverage and ongoing litigation cap multiple expansion
- International segment faces FX and pricing pressure
| Net Income: -1.10b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.57 > 1.0 |
| NWC/Revenue: 18.23% < 20% (prev 15.61%; Δ 2.61% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.80b > Net Income -1.10b |
| Net Debt (19.0b) to EBITDA (2.05b): 9.28 < 3 |
| Current Ratio: 1.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (378.1m) vs 12m ago 1.34% < -2% |
| Gross Margin: 71.82% > 18% (prev 70.70%; Δ 1.12% > 0.5%) |
| Asset Turnover: 41.69% > 50% (prev 36.15%; Δ 5.54% > 0%) |
| Interest Coverage Ratio: 0.54 > 6 (EBIT TTM 875.0m / Interest Expense TTM 1.61b) |
| A: 0.08 (Total Current Assets 6.52b - Total Current Liabilities 4.54b) / Total Assets 24.8b |
| B: -0.44 (Retained Earnings -10.8b / Total Assets 24.8b) |
| C: 0.03 (EBIT TTM 875.0m / Avg Total Assets 26.0b) |
| D: -0.07 (Book Value of Equity -1.77b / Total Liabilities 25.6b) |
| Altman-Z'' = -0.75 = B |
| DSRI: 0.93 (Receivables 2.26b/2.21b, Revenue 10.9b/9.86b) |
| GMI: 0.98 (GM 70.70% / 71.82%) |
| AQI: 0.95 (AQ_t 0.65 / AQ_t-1 0.69) |
| SGI: 1.10 (Revenue 10.9b / 9.86b) |
| TATA: -0.12 (NI -1.10b - CFO 1.80b) / TA 24.8b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of August 15, 2026, the stock is trading at USD 6.51 with a total of 2,281,896 shares traded. Over the past week, the price has changed by +4.16%, over one month by +37.05%, over three months by +19.45% and over the past year by -13.32%.
Current recommended Stop Loss: 5.60 (which is 14% or 2.5 ATR below the current price).
Bausch Health Companies has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold BHC.
- StrongBuy: 0
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 7.5 | 15.2% |
P/E Forward = 1.3829
P/S = 0.2154
P/B = 18.7773
P/EG = 0.011
Revenue TTM = 10.9b USD
EBIT TTM = 875.0m USD
EBITDA TTM = 2.05b USD
Long Term Debt = 19.9b USD (from longTermDebt, last quarter)
Short Term Debt = 881.0m USD (from shortTermDebt, last quarter)
Debt = 20.8b USD (from shortLongTermDebtTotal, last quarter) + Leases 38.0m
Net Debt = 19.0b USD (calculated: Debt 20.8b - CCE 1.82b)
Enterprise Value = 21.3b USD (2.34b + Debt 20.8b - CCE 1.82b)
Interest Coverage Ratio = 0.54 (Ebit TTM 875.0m / Interest Expense TTM 1.61b)
EV/FCF = 15.32x (Enterprise Value 21.3b / FCF TTM 1.39b)
FCF Yield = 6.53% (FCF TTM 1.39b / Enterprise Value 21.3b)
FCF Margin = 12.83% (FCF TTM 1.39b / Revenue TTM 10.9b)
Net Margin = -10.12% (Net Income TTM -1.10b / Revenue TTM 10.9b)
Gross Margin = 71.82% ((Revenue TTM 10.9b - Cost of Revenue TTM 3.06b) / Revenue TTM)
Gross Margin QoQ = 72.93% (prev 70.76%)
Tobins Q-Ratio = 0.86 (Enterprise Value 21.3b / Total Assets 24.8b)
Interest Expense / Debt = 7.72% (Interest Expense 1.61b / Debt 20.8b)
Taxrate = 25.29% (88.0m / 348.0m)
NOPAT = 653.7m (EBIT 875.0m * (1 - 25.29%))
Current Ratio = 1.44 (Total Current Assets 6.52b / Total Current Liabilities 4.54b)
Debt / Equity = -11.75 (negative equity) (Debt 20.8b / totalStockholderEquity, last quarter -1.77b)
Debt / EBITDA = 9.28 (Net Debt 19.0b / EBITDA 2.05b)
Debt / FCF = 13.64 (Net Debt 19.0b / FCF TTM 1.39b)
Total Stockholder Equity = -1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.22% (Net Income -1.10b / Total Assets 24.8b)
RoE = 88.77% (negative equity) (Net Income TTM -1.10b / Total Stockholder Equity -1.24b)
RoCE = 4.69% (EBIT 875.0m / Capital Employed (Equity -1.24b + L.T.Debt 19.9b))
RoIC = 3.18% (NOPAT 653.7m / Invested Capital 20.6b)
WACC = 6.26% (E(2.34b)/V(23.2b) * Re(10.60%) + D(20.8b)/V(23.2b) * Rd(7.72%) * (1-Tc(0.25)))
Discount Rate = 10.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 78.95 | Cagr: 1.36%
[DCF] Terminal Value 77.97% ; FCFF base≈1.28b ; Y1≈1.46b ; Y5≈2.15b
[DCF] Fair Price = 35.90 (EV 32.4b - Net Debt 19.0b = Equity 13.4b / Shares 374.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 84.86 | EPS CAGR: 5.69% | SUE: 2.32 | # QB: 1
Revenue Correlation: 99.43 | Revenue CAGR: 8.45% | SUE: 4.0 | # QB: 4
EPS current Quarter (2026-09-30): EPS=1.19 | Chg30d=-6.95% | Revisions=-40% | Analysts=5
EPS current Year (2026-12-31): EPS=4.47 | Chg30d=+1.02% | Revisions=+0% | GrowthEPS=+19.2% | GrowthRev=+6.0%
EPS next Year (2027-12-31): EPS=4.19 | Chg30d=-0.58% | Revisions=+0% | GrowthEPS=-6.1% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -22% (up=2, down=4)